New possibilities of hypothyroidism pharmacotherapy: resolution of the expert council
G. A. Melnichenko,
V. V. Fadeev,
N. A. Petunina,
E. A. Troshina,
T. B. Morgunova,
N. V. Mazurina,
L. A. Ruyatkina,
E. N. Kareva https://doi.org/10.14341/ket12834
Abstract
Today, replacement therapy with sodium levothyroxine (L-T4) is the main method of treating hypothyroidism. Replacement therapy with tablet forms of L-T4 is simple, understandable and convenient. However, a significant proportion of patients are in a state of iatrogenic thyrotoxicosis or uncompensated hypothyroidism. The reasons for unsatisfactory compensation are both violations of the pill regimen, including missed doses, and lifestyle, comorbid conditions or drugs received by the patient that interfere with the selection of the optimal dose. Today, not only tablets are used in the world, but also other forms of L-T4, for example, an oral solution and gel capsules. In March 2024, a liquid levothyroxine drug was registered in Russia. In this article, we will consider the practical features of prescribing this drug and its differences from tablet forms.
About the Authors
G. A. Melnichenko
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Galina A. Melnichenko, MD, Dr. Sci. (Medicine), Professor, Academician of the Russian Academy of Sciences
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов, связанных с публикацией данной статьи
V. V. Fadeev
I.M. Sechenov First Moscow State Medical University
Competing Interests:
Valentin V. Fadeev, MD, Dr. Sci. (Medicine), Professor, Corresponding Member of the Russian Academy of Sciences
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов, связанных с публикацией данной статьи
N. A. Petunina
I.M. Sechenov First Moscow State Medical University
Competing Interests:
Nina A. Petunina, MD, Dr. Sci. (Medicine), Professor
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов, связанных с публикацией данной статьи
E. A. Troshina
Endocrinology Research Centre
Competing Interests:
Ekaterina A. Troshina, MD, MD, Dr. Sci. (Medicine), Professor, Corresponding Member of the Russian Academy of Sciences
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов, связанных с публикацией данной статьи
T. B. Morgunova
I.M. Sechenov First Moscow State Medical University
Competing Interests:
Tatyana B. Morgunova, MD, Cand. Sci. (Medicine)
8 Trubetskaya str., build. 2, Moscow, 119048
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов, связанных с публикацией данной статьи
N. V. Mazurina
Endocrinology Research Centre
Competing Interests:
Natalia V. Mazurina, MD, Dr. Sci. (Medicine)
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов, связанных с публикацией данной статьи
L. A. Ruyatkina
Novosibirsk State Medical University
Competing Interests:
Lyudmila A. Ruyatkina, MD, Dr. Sci. (Medicine), Professor
Novosibirsk
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов, связанных с публикацией данной статьи
E. N. Kareva
I.M. Sechenov First Moscow State Medical University
Competing Interests:
Elena N. Kareva, MD, Dr. Sci. (Medicine), Professor
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов, связанных с публикацией данной статьи
References
1. Taylor PN, Iqbal A, Minassian C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med. 2014 Jan;174(1):32-9. doi: 10.1001/jamainternmed.2013.11312.
2. Molewijk E, Fliers E, Dreijerink K, et al. Quality of life, daily functioning, and symptoms in hypothyroid patients on thyroid replacement therapy: A Dutch survey. J Clin Transl Endocrinol. 2024 Feb 2;35:100330. doi: 10.1016/j.jcte.2024.100330.
3. Yavuz DG, Yazıcı D, Keskin L, et al. Out-of-Reference Range Thyroid-Stimulating Hormone Levels in Levothyroxine-Treated Primary Hypothyroid Patients: A Multicenter Observational Study. Front Endocrinol (Lausanne). 2017 Sep 12;8:215. doi: 10.3389/fendo.2017.00215.
4. Janett-Pellegri C, Wildisen L, Feller M, et al. Prevalence and factors associated with chronic use of levothyroxine: A cohort study. PLoS One. 2021 Dec 20;16(12):e0261160. doi: 10.1371/journal.pone.0261160.
5. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751. doi: https://doi.org/10.1089/thy.2014.0028
6. Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal Malabsorption of Thyroxine. Endocr Rev. 2019;40(1):118-136. doi: https://doi.org/10.1210/er.2018-00168
7. Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012;62(12):631-6. doi: https://doi.org/10.1055/s-0032-1329951
8. Bornikowska K, Gietka-Czernel M, Raczkiewicz D, et al. Improvements in Quality of Life and Thyroid Parameters in Hypothyroid Patients on Ethanol-Free Formula of Liquid Levothyroxine Therapy in Comparison to Tablet LT4 Form: An Observational Study. J Clin Med. 2021;10(22):5233. doi: https://doi.org/10.3390/jcm10225233
Review
For citations:
Melnichenko G.A., Fadeev V.V., Petunina N.A., Troshina E.A., Morgunova T.B., Mazurina N.V., Ruyatkina L.A., Kareva E.N. New possibilities of hypothyroidism pharmacotherapy: resolution of the expert council. Clinical and experimental thyroidology. 2025;21(2):14-17. (In Russ.) https://doi.org/10.14341/ket12834
Views:
26
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
